125 related articles for article (PubMed ID: 11599105)
21. hTERT gene amplification and clinical significance in pleural effusions of patients with lung cancer.
Cha N; Li XY; Zhao YJ; Wang EH; Wu GP
Clin Lung Cancer; 2012 Nov; 13(6):494-9. PubMed ID: 22464057
[TBL] [Abstract][Full Text] [Related]
22. Positive effusion cytology as the initial presentation of malignancy.
Monte SA; Ehya H; Lang WR
Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
[TBL] [Abstract][Full Text] [Related]
23. Cytomorphological profile of neoplastic effusions: an audit of 10 years with emphasis on uncommonly encountered malignancies.
Gupta S; Sodhani P; Jain S
J Cancer Res Ther; 2012; 8(4):602-9. PubMed ID: 23361282
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic implications of telomerase activity in pleural effusions.
Dikmen G; Dikmen E; Kara M; Sahin E; Doğan P; Ozdemir N
Eur Respir J; 2003 Sep; 22(3):422-6. PubMed ID: 14516130
[TBL] [Abstract][Full Text] [Related]
25. Cytology and flow cytometry of malignant effusions of multiple myeloma.
Palmer HE; Wilson CS; Bardales RH
Diagn Cytopathol; 2000 Mar; 22(3):147-51. PubMed ID: 10679993
[TBL] [Abstract][Full Text] [Related]
26. Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry.
Risberg B; Davidson B; Nielsen S; Dong HP; Christensen J; Johansen P; Asschenfeldt P; Berner A
Diagn Cytopathol; 2001 Oct; 25(4):214-9. PubMed ID: 11599103
[TBL] [Abstract][Full Text] [Related]
27. Development of a sensitive, specific reverse transcriptase polymerase chain reaction-based assay for epithelial tumour cells in effusions.
Sakaguchi M; Virmani AK; Ashfaq R; Rogers TE; Rathi A; Liu Y; Kodagoda D; Cunningham HT; Gazdar AF
Br J Cancer; 1999 Feb; 79(3-4):416-22. PubMed ID: 10027307
[TBL] [Abstract][Full Text] [Related]
28. Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis.
Gupta P; Pandey T; Gautam U; Rajwanshi A; Srinivasan R; Gupta N; Rohilla M; Varma N; Dey P
Diagn Cytopathol; 2021 May; 49(5):647-656. PubMed ID: 33629825
[TBL] [Abstract][Full Text] [Related]
29. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
30. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
31. Value of DNA analysis in addition to cytological testing in the diagnosis of malignant pleural effusions.
Rodríguez de Castro F; Molero T; Acosta O; Julià-Serdà G; Caminero J; Cabrera P; Carrillo T
Thorax; 1994 Jul; 49(7):692-4. PubMed ID: 8066565
[TBL] [Abstract][Full Text] [Related]
32. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions.
Fiegl M; Haun M; Massoner A; Krugmann J; Müller-Holzner E; Hack R; Hilbe W; Marth C; Duba HC; Gastl G; Grünewald K
J Clin Oncol; 2004 Feb; 22(3):474-83. PubMed ID: 14752070
[TBL] [Abstract][Full Text] [Related]
33. Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma.
Fiegl M; Kaufmann H; Zojer N; Schuster R; Wiener H; Müllauer L; Roka S; Huber H; Drach J
Hum Pathol; 2000 Apr; 31(4):448-55. PubMed ID: 10821492
[TBL] [Abstract][Full Text] [Related]
34. An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions.
Kentrou NA; Tsagarakis NJ; Tzanetou K; Damala M; Papadimitriou KA; Skoumi D; Stratigaki A; Anagnostopoulos NI; Malamou-Lada E; Athanassiadou P; Paterakis G
Cytometry B Clin Cytom; 2011 Sep; 80(5):324-34. PubMed ID: 21695775
[TBL] [Abstract][Full Text] [Related]
35. Cytological diagnosis of serous effusions in a cancer hospital in Brazil.
Oyafuso MS; Longatto Filho A; Bortolan J; Rahal P; Bisi H; Lombardo V
Pathologica; 1996 Apr; 88(2):128-31. PubMed ID: 8927447
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of clot examination for malignant cells in serous effusions.
Jalal R; Aftab K; Hasan SH; Pervez S
Cytopathology; 2009 Aug; 20(4):231-4. PubMed ID: 18627403
[TBL] [Abstract][Full Text] [Related]
37. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
38. Application of multicolour flow cytometry in the detection of metastatic carcinoma in serous effusions: Special emphasis in atypical cytology.
Sahu S; Gupta P; Susheilia S; Gautam U; Dey P
Cytopathology; 2021 Mar; 32(2):169-179. PubMed ID: 33040400
[TBL] [Abstract][Full Text] [Related]
39. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
40. Cytomorphology, Immunophenotype, and cytogenetic profile of leukemic serous effusions.
Kaur K; Patel T; Patra S; Trivedi P
Diagn Cytopathol; 2021 Aug; 49(8):948-958. PubMed ID: 33973738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
